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A Major Susceptibility Locus for Systemic Lupus Erythemathosus Maps
to Chromosome 1q31
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The Collaborative Group on the Genetics of SLE,* The BIOMED II Collaboration
on the Genetics of SLE and Sjo¨grens Syndrome,* and Marta E. Alarco´n-Riquelme1
1Institute of Genetics and Pathology, Section for Medical Genetics, University of Uppsala, Uppsala, Sweden; and 2Department
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A set of 87 multicase families with systemic lupus erythemathosus (SLE) from European (Iceland, Sweden, England,
Norway, Italy, and Greece) and recently admixed (Mexico, Colombia, and the United States) populations were
genotyped and analyzed for 62 microsatellite markers on chromosome 1. By parametric two-point linkage analysis,
six regions (1p36, 1p21, 1q23, 1q25, 1q31, and 1q43) were identified that have LOD scores of , withZ  1.50
different contributions, depending on the population of origin of the families (European or admixed American).
All of the regions have been described previously and have therefore been confirmed in this analysis. The locus at
1q31 showed a significant three-point LOD score of and was contributed by families from all populations,Zp 3.79
with several markers and under the same parametric model. Analysis of a known mutation in the CD45 gene did
not support the role that this mutation plays in disease. We conclude that the locus at 1q31 contains a major
susceptibility gene, important to SLE in general populations.
Introduction
Systemic lupus erythemathosus (SLE [MIM 152700]) is
one of several common autoimmune diseases, such as pso-
riasis (MIM 177900), rheumatoid arthritis (MIM 180300),
Graves disease (MIM 275700), diabetes type 1 (MIM
222100), and multiple sclerosis (MIM 126200). Ap-
proximately 4%–5% of the population is affected with
some type of autoimmune disease, thus making it a ma-
jor health problem. Females are generally affected more
often than male individuals are (Hochberg 1987; Vyse
and Todd 1996).
Little is known about the predisposing factors and
mechanisms leading to SLE, but some of these may in-
volve loss of immunologic tolerance to intracellular an-
tigens, primarily nuclear antigens. Autoantibodies to such
components represent a main feature of SLE.
Family-based studies show a 10%–12% increased risk
for relatives of patients with SLE, and asymptomatic rel-
atives often have immunologic abnormalities (Hochberg
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1987; Lawrence et al. 1987). The familial aggregation
(l value) for SLE is estimated to be between 20 and
58 (Hochberg 1985, 1987; Lawrence et al. 1987; Gud-
mundsson and Steinsson 1990; Jonsson et al. 1990).
Concordance rates between MZ twins vary from 25%
to 69%, which is 110 times higher than that between
DZ twins (1%–2%) (Deapen et al. 1992; Jarvinen and
Aho 1994). Together, these data indicate that there is
a relatively high genetic component behind SLE and
point toward an oligogenic background, with several
susceptibility genes acting on disease expression along
with environmental factors.
During recent years, six complete (Gaffney et al. 1998,
2000; Moser et al. 1998; Shai et al. 1999; Gray-McGuire
et al. 2000; Lindqvist et al. 2000) and five partial (Tsao
et al. 1997, 1999, 2001; Moser et al. 1999; Graham
et al. 2001) scans of the human genome have been
performed on multicase families with SLE. A total of
48 potential susceptibility loci have been identified.
However, only six regions linked to SLE met the
Lander and Kruglyak (1995) threshold of genome-
wide significance (maximum LOD score [Z] 3.3):
1q23-24 (Moser et al. 1998), 1q41-43 (SLEB1 [MIM
601744]) (Moser et al. 1998; Tsao et al. 1999), 2q37
(SLEB2 [MIM 605218]) (Lindqvist et al. 2000), 4p16-
15.2 (SLEB3 [MIM 605480]) (Moser et al. 1998), 6p21-
11 (Gaffney et al. 1998), and 16q13 (Gaffney et al. 1998).
Chromosome 1 is replete with genes of relevance to
immune responses, and this may be one of the reasons
why linkage to SLE has been detected at so many regions
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on this chromosome. At least seven potential loci have
been linked to SLE on chromosome 1 (identified as hav-
ing a LOD score of 1.5). These are at 1p36, 1p21, 1p13,
1q21, 1q23-24, 1q25, and 1q31. Furthermore, a broad
region at 1q41-43 probably consists of two or more
loci. Only 1q23-24 and 1q41-43 have been linked with
a significant LOD score (i.e., 13.30), and only the 1q41-
43 region has been confirmed, in a different study, as
having at least a suggestive LOD score (i.e., 12.20).
Not surprisingly, when different studies are compared,
different results are obtained. One explanation for this
divergence is that different analytical methods, genetic
maps, and markers have been used. Another explana-
tion for the divergence in results between studies is that
SLE is a multifactorial and heterogeneous disease with
presumably different contributing susceptibility factors.
Striking differences in incidence, prevalence, and the clin-
ical pattern between different ethnic populations found in
several epidemiological studies support this view (Green-
wood 1968; Samanta et al. 1992; Hopkinson et al. 1993,
1994, 2000; Adebajo and Davis 1994; Johnson et al.
1995; McCarty et al. 1995; Karlson et al. 1997; Malaviya
et al. 1997; Molina et al. 1997; Wang et al. 1997; Bae
et al. 1998; Molokhia et al. 2001). Although the studies
have used different methods of assessment that make it
difficult to compare them, a rough picture emerges in
which at least African American, African Caribbean,
and Chinese populations have higher incidences of
SLE (two- to fourfold higher) than patients from dif-
ferent European populations. No epidemiological data
are available for the Mexican or Mexican American
populations. In general, the data indicate that environ-
mental factors, as well as genetic heterogeneity between
and within populations, influences the susceptibility to
SLE. The varying results reflect, at least in part, that
different studies have had access to families from dif-
ferent ethnicities and geographical regions. To analyze
chromosome 1, we used 62 microsatellite markers in a
new set of 87 multicase families from European and
recently admixed American populations.
Families, Material, and Methods
Families
Eighty-seven multicase families from 11 countries in
Europe and the Americas (mainly Mexico and Colom-
bia) were recruited through international multicenter
collaborations. Multicase families were included when
at least two individuals in the families were considered
as having SLE by fulfilling four or more of the 1982
American College of Rheumatology criteria (Tan et al.
1982). Individuals having either fewer than four clinical
manifestations or other manifestations compatible with
unspecific autoimmune disease and all healthy individ-
uals aged !30 years were assigned the phenotype “un-
known” in the analyses. The families participating in the
study provided informed consent, and permission from
the local ethical committees was obtained. The families
included both nuclear families and extended pedigrees.
Seven of the 10 Icelandic families and 11 of the 14 Swed-
ish families constitute an initial set used in our previous
genome scan (Lindqvist et al. 2000) and are therefore
overlapping.
Genotyping
Genotyping was performed using fluorescent-labeled
primers for microsatellite markers. The primers were dye-
conjugated with FAM, HEX, or TET (Thermo Hybaid,
Interactiva Division) or NED (Applied Biosystems). The
PCR amplification was performed using a Peltier thermal
cycler (PTC-225; MJ Research). Each reaction was per-
formed in a volume of 10 ml (containing 17 ng genomic
DNA, 1–2.5 mM MgCl2, 1# PCR buffer [Applied Bio-
systems], 200 mM each dNTP [Amersham Pharmacia Bio-
tech], 1.5 pmol each primer, and 0.17 U AmpliTaq Gold
DNA Polymerase [Applied Biosystems]). PCR amplifi-
cation consisted of an initial step at 95C for 10 min; 9
cycles of denaturation at 95C for 30 s, annealing at 50C,
55C, or 60C for 45 s, and extension at 72C for 45 s;
19 cycles of denaturation at 89C for 15 s, annealing at
50C, 55C, or 60C for 45 s, and extension at 72C for
45 s; and a final step at 72C for 7 min.
Products from up to eight different PCRs were diluted
1:10 (1:5 for products labeled with HEX and NED) and
were pooled together. Two microliters of the pooled re-
actions were then mixed with 2 ml TAMRA size standard
GS-350 or GS-500 and were diluted 1:2 with loading
buffer (50 mg/ml blue dextran; 25 mM EDTA) (Applied
Biosystems). The pooled reactions were denaturated at
95C for 1 min and were loaded on an ABI 377 DNA
analyzer (Applied Biosystems) with a 4% polyacrylamide
gel and a 36-cm well-to-read plate. The data were col-
lected with the GeneScan analysis software, version 3.1
(Applied Biosystems).
Alternatively, the PCR amplification was performed us-
ing ABI 877 integrated thermal cyclers (Applied Biosys-
tems) under the same conditions as described above, and
the products were pooled automatically. After pooling, 1
ml of the pooled reactions was mixed with 10 ml ROX
size standard 400 HD or 500 HD, was diluted 1:56 with
HI-DI formamide (Applied Biosystems), was denaturated
at 95C for 1 min, and was loaded on an ABI 3700 DNA
analyzer (Applied Biosystems). The data were collected
using the GeneScan analysis software, version 3.5.1 (Ap-
plied Biosystems).
Allele calling was performed using Genotyper, version
2.1 (Applied Biosystems). Inconsistent inheritance, bin,
and allele calling was performed using the GAS software
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package, version 2.0 (Alan Young, Oxford University).
The allele frequencies were conservatively calculated from
the family material—first for all of the families jointly and
second for each of the two geographical subgroups, with
all individuals typed in the families.
Fifty-nine of the 62 markers used in this study were
positioned according to the Marshfield sex-averaged ge-
netic map (Broman et al. 1998). Three markers (D1S170,
D1S171, and D1S3469) were not found in the genetic
map but were located, using BLAST, in the Ensembl hu-
man genome sequence (version 5.29.1; May 12, 2002,
freeze) (Hubbard et al. 2002), and were positioned in the
genetic map according to their distance to neighboring
markers in the genome sequence. Four of the markers
(D1S1609, D1S1679, D1S2675, and D1S2844) had a dif-
ferent order in the genetic map compared to the genome
sequence, and, for consistency, the genetic map was used.
Statistical Analysis
To use all available information from the pedigrees,
we selected a parametric-LOD-score method. Two-point
and multipoint LOD scores were calculated by using the
ANALYZE software package, version 2.1 (Terwilliger
1995), and the FASTLINK software package, version
4.0P (Cottingham et al. 1993; Scha¨ffer et al. 1994).
All linkage analyses were calculated under the as-
sumption of locus heterogeneity by using the admix-
ture test (Smith 1963), which was performed by the
HOMOG routine, version 3.35, in the ANALYZE
software (Ott 1991). This functions as a simple two-
locus test in which only one or the other (or neither)
of two unlinked susceptibility loci (with the same
genetic risk and inheritance model) have an effect in
each family. The proportion of families with linkage
for a given marker is expressed as a.
We used three screening inheritance models, as de-
scribed in our original genome-scan study of Scandi-
navian populations (Lindqvist et al. 2000). These were
designated to fit the assumption of a “common” or a
“rare” single dominant disease allele (with frequencies
of 0.02 and 0.002, respectively) or a “common” single
recessive disease allele (with a frequency of 0.03 in the
population). To take into consideration the different
prevalences for male and female patients with SLE, we
established two liability classes in which females had
eight times higher penetrance than males did. The male
and female penetrance values, respectively, in the dom-
inant (50% and 6.25%) and the recessive (70% and
8.75%) models were set so that they, together with the
disease-allele frequency, fitted the observed prevalence
of SLE found in northern European populations (Gud-
mundsson and Steinsson 1990). We also used the screen-
ing inheritance models applied in the genome scan by
Moser et al. (1998), also using a parametric-LOD-score
method. Their screening models are based on the as-
sumption of an“autoimmune” disease allele with a fre-
quency of (Bias et al. 1986). The models hadpp 0.10
the following penetrances: two models had a “high”
penetrance in both sexes (90% in the dominant model
and 100% in the recessive model), two models had a
“low” penetrance in both sexes (50% in both the dom-
inant model and the recessive model), and two models
had a high penetrance in females and a low penetrance
in males (95% and 49%, respectively, in both the dom-
inant model and the recessive model).
Genotyping of the CD45 Exon 4 Mutation
The primers used for the detection of the CD45
(MIM 151460) exon 4 G77C mutation were as fol-
lows: forward primer, 5′-ATTTATTTTGTCCTTC-
TCCCA-3′, and reverse primer: 5′-GTTAACAACT-
TTTGTGTGCC-3 ′ (Thermo Hybaid). The PCR
amplification was performed with a Peltier thermal
cycler (PTC-225; MJ Research). Each reaction was
performed in a volume of 10 ml (containing 34 ng
genomic DNA, 1.5 mM MgCl2, 1# PCR buffer [Ap-
plied Biosystems], 200 mM each dNTP [Amersham
Pharmacia Biotech], 0.17 U AmpliTaq Gold DNA
Polymerase [Applied Biosystems], and 1.5 pmol each
primer). The PCR amplification consisted of an initial
step at 95C for 10 min; 11 cycles of denaturation at
95C for 30 s, annealing at 54C for 45 s, and exten-
sion at 72C for 45 s; 22 cycles of denaturation at
89C for 15 s, annealing at 54C for 45 s, and exten-
sion at 72C for 45 s; and a final step at 72C for 7
min. The 10 ml of amplified PCR product was digested
with 1 U of MspI restriction enzyme (New England
Biolabs) and 1# NE-Buffer2 (New England Biolabs),
in a total volume of 15 ml. The reaction was incubated
at 37C for 3 h. The enzyme was denaturated at 64C
for 20 min. The digested DNA was blotted on a 3%
SeaKem LE agarose gel (BioWhittaker Molecular Ap-
plications) and was stained with ethidium bromide.
Results
The geographical distribution and the characteristics of
the families are shown in table 1. The mean female:male
ratio among all affected individuals was 7.3:1. Forty-four
families were from Europe, and 37 families were from
the Americas, mainly from Mexico ( ); a separatenp 30
group of 6 families were Chinese from Singapore. We
decided to analyze the families from the Americas together
and to consider them as a group of recent admixture
(Gorodezky et al. 2001; Cerda-Flores et al. 2002), in order
to have a group comparable to the European families.
The six Chinese families were considered only when all
families were analyzed jointly. In total, 576 individuals
were genotyped, of whom 191 were affected.
In a first step, an initial screening for microsatellites
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Table 1
Total Number of Individuals and Number of Patients with SLE, Distributed among Countries
and Geographical Areas Used in the Analysis
Country Families Typed
Total Affected
Individuals
Affected
Males
Affected
Females
Female:Male
Ratio
Eu:
Swedena 14 73 34 5 29 5.8:1
Icelanda 10 110 25 3 22 7.3:1
Italya 6 40 12 3 9 3.0:1
Norwaya 6 29 13 0 13 …
Englanda 6 19 12 0 12 …
Greecea 2 10 4 1 3 3.0:1
Overall 44 281 100 12 88 7.3:1
Am:
Mexicob 30 205 65 7 58 8.3:1
Colombiab,c 4 40 7 0 7 …
United Statesa,c 2 8 5 0 5 …
Jamaicac 1 4 2 0 2 …
Overall 37 257 79 7 72 10.9:1
Singapored 6 38 12 4 8 2.0:1
Overall 87 576 191 23 168 7.3:1
NOTE.—Eu p European families; Am p American admixed families; All p all families.
a Whites.
b Mestizos (mainly Native American and Spanish admixture).
c African Caribbeans/Americans.
d Chinese.
along the whole of chromosome 1 was performed us-
ing 26 markers from the Cooperative Human Linkage
Center/Weber screening set, version 6. The markers
had 80% of individuals typed, an average polymor-
phism information content (PIC) value of 0.73, and a
mean intermarker distance of 10.81 cM.
Altogether, 17 markers gave LOD scores 1.50. To-
gether, these were distributed around seven chromo-
somal regions identified by either one or several mark-
ers, separated from each other by !15 cM. The results
are shown in table 2.
A region on the short arm of chromosome 1, at
1p36, was detected with one marker contributed only
by American families ( , under the recessiveZp 3.06
model). Also, a region at 1p21 showed contribution
only from American families for two markers, together
spanning 0.5 cM with a dominant model (Zp 1.51
and ). In the long arm of chromosome 1, theZp 2.17
region 1q23-q24 was detected with both American
( ) and European ( ) families. Both useZp 2.24 Zp 1.65
a recessive inheritance model, but with two different
markers, together spanning an interval of 14 cM. Only
families from Europe contributed to the linkage at 1q25.
The linkage was positive with two markers, spanning
a 2-cM interval ( and , under theZp 2.23 Zp 1.71
dominant model). At 1q31, three markers gave the
highest LOD scores when all of the families were an-
alyzed together (Zp 2.73, Zp 3.33, and Zp 2.17),
all with the same recessive model of inheritance. Link-
age at 1q32.3 ( ) was identified with a singleZp 1.86
marker for all families using a dominant model con-
tributed by both groups ( [European families]Zp 1.22
and [American families]), but the EuropeanZp 1.31
families showed linkage using recessive models as well
(Z p 1.76). Finally, we also detected linkage with a
single marker located at 1q43 ( , under theZp 1.54
recessive model). This marker showed linkage only when
all families were analyzed jointly. Unfortunately, ampli-
fication for adjacent markers was not obtained, giving a
gap of 20 cM to the nearest marker.
In a second step, 36 markers were included to fine map
the 1p36 and 1q31 regions and to reduce gaps from the
initial screening, giving a total set of 62 markers. With
all markers combined, the average PIC value was 0.74,
and the mean intermarker distance was reduced to 2.89
cM. At 1p36, a second marker, 1 cM from the original
marker, confirmed the exclusive contribution by the
American families ( ), but with a lower LODZp 1.61
score and a dominant model (table 3).
In contrast, several of the additional markers at 1q31
gave LOD scores 11.50 in all families, assuming the same
recessive model as with the original markers (fig. 1). A
three-point analysis was performed for all of the families,
with D1S1660 and D1S1175. A maximum-multipoint-
LOD-score Z value of 3.79 was obtained under the as-
sumption of heterogeneity and with the same recessive
model that gave the highest LOD scores in the two-point
analyses.
In a final step, since, at this point, we considered
1q31 to be a confirmed susceptibility locus for SLE,
we analyzed CD45, one of the strongest candidate
genes located within the region. CD45 is a protein-
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Table 2
Summary of Chromosomal Regions Linked to SLE, as Detected for Each Geographical
Subset or for All Families Jointly
REGIONa MARKER
DISTANCEb
(cM)
LOD SCORE (MODE, a VALUE)
Eu Am All
p36.33 D1S243 0 .42 (R, .24) 3.06 (R, .46) 2.10 (R, .24)
p21.1 D1S2626 136.34 .01 (D, .98) 1.51 (D, .42) .51 (D, .14)
p21.1 D1S1631 136.88 neg 2.17 (D, 1.00) .27 (D, 1.00)
q23.1 D1S1595 161.05 .27 (R, .14) 2.24 (R, 1.00) 1.96 (R, .42)
q24.2 D1S2844 175.03 1.65 (R, .23) .70 (D, 1.00) 1.38 (R, .15)
q25.1 D1S1589 192.05 2.23 (D, 1.00) .03 (R, .33) .88 (D, 1.00)
q25.2 D1S212 193.76 1.71 (D, 1.00) .13 (R, .11) .67 (D, 1.00)
q31.3 D1S413 212.44 1.65 (R, .24) 1.86 (R, .73) 2.73 (R, .36)
q31.3 D1S1660 212.44 1.88 (R, .25) 2.08 (R, .37) 3.33 (R, .26)
q32.1 D1S2738 215.17 1.41 (R, .21) 1.63 (R, .50) 2.17 (R, .25)
q32.3 D1S425 231.11 1.76 (R, .34) 1.31 (D, .36) 1.86 (D, .37)
q43 D1S547 267.51 .48 (R, .11) .64 (R, .21) 1.54 (R, .12)
NOTE.—The values give the two-point LOD scores, assuming heterogeneity, and “neg”
denotes LOD score 0.0. Values in boldface italic give the highest maximum LOD score,
Z, obtained for this marker. Inside the parentheses, “R” denotes recessive model, “D”
denotes dominant model, and the value given is the a value at that marker. Eup European
families; Am p American admixed families; All p all families.
a Cytogenetic region in Ensembl physical map.
b Sex-averaged distance from the top in the Marshfield genetic map.
tyrosine-phosphatase receptor that has recently been
shown to have a possible role in autoimmunity (Ma-
jeti et al. 2000). A mutation in a splicing-silencer
element on exon 4, at position 77 (C/G), has recently
been found that is associated with multiple sclerosis
in three independent sets of German patients (Jacob-
sen et al. 2000). This mutation affects the splicing of
exon 4, leading to the aberrant expression of CD45
isoforms on activated and memory T cells. To deter-
mine whether the C77G mutation is associated with
SLE in the present set of families, we genotyped 70
patients with SLE from the families that contributed
to the LOD score. The mutation was found in the
heterozygous form in two of three individuals with
SLE from a single Swedish family, thus excluding this
mutation as a contributor to the LOD score that we
observed. It cannot be excluded that other mutations
presently unknown in CD45 could contribute to the
linkage or that a gene nearby is involved in SLE sus-
ceptibility at this major locus.
Discussion
In the present study, we provide significant evidence for
linkage to a locus at 1q31. Furthermore, our results
show that there is a large extent of genetic heterogeneity
at most of the loci where we observed linkage. For each
locus, linkage was contributed by a small proportion of
families. The exceptions were D1S1631 (on 1p21), both
markers on 1q23 in American families, and both mark-
ers on 1q25 in European families. In these, all families
contributed to the linkage observed.
The European families in the present study contributed
minimally to the linkage at previously defined regions on
chromosome 1 in U.S. populations (1p36, 1p13, 1p21,
1q23-24, and 1q41), partly explaining why our own pre-
vious genome scan on Nordic families did not detect these
(Lindqvist et al. 2000). In contrast, the admixed Amer-
ican families unambiguously confirmed (with a threshold
LOD score of ) nearly all of the previously iden-Zp 1.5
tified regions, with the exceptions of 1p13 and 1q41. A
summary of the loci identified in the present study and
in previous studies is shown in table 4.
We previously identified 1q31 in the subset of Swed-
ish multicase families, using D1S1660 (Lindqvist et al.
2000). In the present study, this marker showed the
highest LOD score with all families analyzed jointly in
the two-point analysis ( , under the recessiveZp 3.33
model). When a three-point analysis was performed us-
ing D1S1660 and the neighboring marker D1S1175, the
LOD score increased to for D1S1660. TwoZp 3.79
other markers in this region also gave LOD scores of
, when the same recessive inheritance modelZ 1 2.00
was used.
Two interesting candidate genes are located near the
highest LOD-score peak—complement factor H (HF1
[MIM 134370]) and protein-tyrosine-phosphatase re-
ceptor C (CD45, or PTPRC) (fig. 1). In fact, both of
the markers (D1S1660 and D1S413) that give the high-
est LOD scores are placed within the CD45 gene.
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Table 3
Fine Mapping of 1p36 by Two-Point Analysis, as Detected for Each Geographical
Subset or for All Families Jointly
REGIONa MARKER
DISTANCEb
(cM)
LOD SCORE (MODE, a VALUE)
Eu Am All
p36.33 D1S243 0 .42 (R, .24) 3.06 (R, .46) 2.10 (R, .24)
p36.32 D1S171 1.0c neg 1.61 (D, .95) .61 (D, .16)
p36.32 D1S468 4.22 .06 (R, .66) .67 (D, .56) .53 (R, .08)
p36.32 D1S2660 10.78 neg .51 (D, 1.00) .11 (D, .07)
p36.31 D1S2795 11.87 .67 (R, .24) neg .01 (R, .02)
p36.31 D1S214 14.04 neg .01 (D, 1.00) .01 (D, 1.00)
p36.23 D1S1612 16.22 .04 (R, .04) 1.37 (D, 1.00) .82 (D, 1.00)
p36.22 D1S434 29.93 neg .41 (D, 1.00) .04 (D, 1.00)
p36.13 D1S170 40.0c .23 (D, 1.00) 1.35 (D, 1.00) 1.20 (D, 1.00)
p36.13 D1S552 45.33 .01 (D, 1.00) .47 (D, 1.00) .17 (D, 1.00)
NOTE.—The values give the two-point LOD scores, assuming heterogeneity, and “neg”
denotes LOD score 0.0. Values in boldface italic give the highest maximum LOD score,
Z, obtained for this marker. Inside the parentheses, “R” denotes recessive model, “D”
denotes dominant model, and the value given is the a value at that marker. EupEuropean
families; Am p American admixed families; All p all families.
a Cytogenetic region in the Ensembl physical map.
b Sex-averaged distance from the top in the Marshfield genetic map.
c Genetic distance estimated from Ensembl genome sequence.
CD45 is involved in the regulation of the antigen-in-
duced signaling of naive B and T cells (Trowbridge
and Thomas 1994). CD45-knockout mice are severely
immunodeficient because of impaired positive selection
in the thymus, leading to the presence of very few T
cells in the periphery. Also, the antigen-receptor–me-
diated signal transduction is significantly reduced in
both T and B cells (Kishihara et al. 1993; Byth et al.
1996). In humans, two children with severe combined
immunodeficiency have been found who have deletions
in the CD45 gene (Cale et al. 1997; Kung et al. 2000;
Tchilian et al. 2001b). Both children expressed very
low numbers of CD45, resembling the CD45-knock-
out mice. Thus, the presence of CD45 is necessary for
the normal functioning of the immune system. In con-
trast, a “knock-in” mouse with a single-point mutation
in the CD45 gene caused lymphoproliferation, auto-
immune nephritis, and autoantibody production (Ma-
jeti et al. 2000). Majeti et al. (2000) speculated that
the mutation prevents CD45 from reducing its own
positive regulatory activity, which would lower the
threshold necessary for an antigen-receptor–mediated
signal to start activation. This indicates that regulation
of CD45 is critical and can lead to autoimmune disease
if it is disturbed.
Different types of leukocytes express different num-
bers of multiple CD45 isoforms. The isoforms are ob-
tained through differential splicing of exons 4–6 (Streuli
et al. 1987). Normally, B cells and naive T cells express
the high-molecular-weight CD45RA isoform, and ac-
tivated and memory T cells express the low-molecular-
weight CD45RB and CD45RO isoforms. A C77G mu-
tation in a splicing element on exon 4 has been found
to prevent normal splicing of this exon (Schwinzer and
Wonigeit 1990; Thude et al. 1995; Lynch and Weiss
2001; Tchilian et al. 2001a). This results in the aberrant
expression of the high-molecular-weight isoform in ac-
tivated and memory T cells. Recently, this mutation was
identified in patients with the autoimmune disease mul-
tiple sclerosis in three independent sets of Germans, but
later studies have been unable to confirm this associa-
tion (Jacobsen et al. 2000; Barcellos et al. 2001). As-
sociation was also not found in other autoimmune dis-
orders, such as diabetes type 1 and Graves disease
(Tchilian et al. 2002; Wood et al. 2002). We were also
unable to find an association between the C77G mu-
tation and the patients with SLE in the families that we
studied. Abnormalities in the CD45 phosphatase activ-
ity have been described in SLE (Takeuchi et al. 1997),
and other mutations may play a role in this disease.
Therefore, the CD45 gene cannot be excluded as a can-
didate gene, and further research is required.
The second-highest LOD score ( , under theZp 3.06
recessive model) identified in the present study was at
1p36. Mexican families contributed most to this ge-
netic linkage, whereas no linkage was found in the
European families. This result is in agreement with
previous findings made by the University of Southern
California (USC) study (Shai et al. 1999), whose region
was attributed to Mexican American families with a
LOD score of ( ) (table 4). ThisNPLp 2.7 Zp 1.58
result and the present study indicate that a suscepti-
bility locus for SLE is located at 1p36 and has its
greatest effect in families of Mexican origin. The
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Figure 1 Fine mapping of the SLE-susceptibility locus at 1q31 in a set of 44 European (from Iceland, Sweden, England, Norway, Italy,
and Greece) and 37 recently admixed American (from Mexico, Colombia, and the United States) multicase families with SLE. The markers in
this figure are analyzed with a two-point LOD, assuming for heterogeneity and with the same recessive screening model. Dots are joined by
lines for the sake of clarity. The markers are located according to the physical location (in Mbp) in Ensembl human sequence. The location of
interesting candidate genes is indicated along the X-axis.
TNFR2 gene (MIM 191191), located within 1p36, has
been considered to be a candidate gene for this region,
and studies of this gene have found a polymorphism
(196M/R) associated with patients with SLE in Japan
(Komata et al. 1999; Morita et al. 2001). Our mul-
tipoint analyses point toward the most telomeric side
of this locus, but the lack of more microsatellite mark-
ers make it difficult for us to define the region better
at this point.
Three other regions—1p21-22, 1q23, and 1q25—
were unambigously identified in the present study, with
LOD scores 2.2, thereby confirming earlier studies
(Moser et al. 1998; Shai et al. 1999; Gray-McGuire et
al. 2000; Tsao et al. 2001) (table 4).
When analyzed in the American families, two markers
indicated a linkage at 1p21, with the strongest signal
of , under a dominant model. As for 1p36,Zp 2.17
this region was previously identified by the study of
Mexican American and European American families
( [ ]) (Shai et al. 1999). There isNPLp 2.56 Zp 1.41
no evident candidate gene for this locus, but several
other genome scans for other autoimmune diseases
have shown linkage for multiple sclerosis (Sawcer et
al. 1996) and Crohn disease (MIM 266600) (Hugot
et al. 1996).
In the present study, two markers 14 cM from each
other confirmed the 1q23 region. When our results are
compared with earlier studies, linkage to this interval is
found with LOD scores 11.5 in most studies, with two
exceptions being the University of Minnesota (MN) study
(Gaffney et al. 1998, 2000) and our genome scan (the
University of Uppsala [UP] study) (Lindqvist et al. 2000).
Most (180%) of the families in the former study were
originally from the Minnesota area, the population of
which has, to a great extent, immigrated from northern
Europe, and the lack of linkage in the MN study was
speculated to be an effect of ethnic heterogeneity (Gaffney
et al. 1998). This hypothesis is in agreement with our
own previous results, which were based only on Swedish
and Icelandic families and in which we did not detect
linkage to 1q23. In addition, none of the northern Eu-
ropean families included in the present study contributed
to linkage to 1q23, and the European contribution to
this locus that we detected was from Italians and Greeks
(data not shown).
Linkage to 1q23 was first identified in the Oklahoma
Medical Research Foundation (OK) study (Moser et
al. 1998). The gene FcgRIIA (MIM 146790) was the
marker giving the highest linkage ( , under theZp 3.37
recessive model) when the families were stratified for
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Table 4
LOD Scores (Z) for Markers at SLE-Susceptibility Regions in Chromosome 1, Identified in the Present
Study and in Other Mapping Studies
REGIONa MARKER
DISTANCEb
(cM)
LOD SCORE (MODE)
UCLAc OKd USCe MNf UPg
1p36 D1S243 0 3.06 Am (R)
D1S468 4.22 1.58 Mex 1.06 All
1p21-22 D1S2868 126.16 1.41 All
D1S1631 136.88 2.17 Am (D)
1p13 D1S252 150.27 1.40 EA (R)h 1.53 All
1q23.1 D1S1595 161.05 2.24 Am (R)
1q23.3 D1S484 169.84 p p .0008 1.51 All
FcgRIIA 170.29 3.37 AA (R)
1q24.2 D1S2844 175.03 1.65 Eu (R)
1q25 D1S1589 192.05 2.23 Eu (D)
Lamc1 ∼199 2.04 All (D)
1q31 D1S1660 212.44 3.33 All (R)
1q32.3 D1S425 231.11 1.86 All (D)
1q41 D1S229 237.73 p p .0005 1.46 EA (D) 1.33 All
D1S2616 239.09 1.23 All
D1S549 239.66 3.30 All
1q42 D1S3462 247.23 3.50 AA (D)
D1S235 254.64 1.92 All
1q43 D1S2785 266.27 2.41 All
D1S547 267.51 1.54 All (R)
NOTE.—Inside the parentheses, “R” denotes recessive model, and “D” denotes dominant model. Am
p admixed Americans; Mx p Mexican Americans; EA p European Americans; All p all families;
AA p African Americans; Eu p Europeans.
a Cytogenetic region in Ensembl physical map.
b Sex-averaged distance (in cM) from the top in the Marshfield genetic map.
c Tsao et al. 1997, 1999, 2001.
d Moser et al. 1998, 1999; Gray-McGuire et al. 2000.
e Shai et al. 1999. Zlr has been converted to LOD score: .
2LODp Z /2 ln 10lr
f Gaffney et al. 1998, 2000; Graham et al. 2001.
g Present study.
h Estimated from figure 2 in Moser et al. 1998.
African American ancestry. Although it had a LOD
score of only ( ) when all of theNPLp 2.56 Zp 1.51
Mexican and European American families were ana-
lyzed together, the 1q23 susceptibility region was con-
sidered to have been confirmed by the USC study (Shai
et al. 1999). The most important candidate genes in
this region are the low-affinity Fcg receptors. Previous
studies (Botto et al. 1996; Salmon et al. 1996; Wu et
al. 1997; Manger et al. 1998; Song et al. 1998) have
identified association with FcgRIIA and FcgRIIIA
(MIM 146740) in various populations, although some
controversy still exists as to whether any of the low-
affinity Fcg receptors are genes for SLE susceptibility
or whether the associated alleles are in linkage dis-
equilibrium with closely linked genes.
Two markers gave linkage at 1q25 in European fam-
ilies, under the assumption of a dominant model, with
LOD scores of Z p 2.23 and Z p 1.71, respectively.
This confirms the linkage at 1q25 found in the OK study
(Moser et al. 1998), by using a polymorphism in the
Lamc1 gene (MIM 150290) and a dominant model on
all families (Z p 2.04). Together, the markers span a
region of 7 cM. This region is 22 cM telomeric from
the low-affinity Fcg receptors but is only 13 cM above
1q31 and is therefore not clearly separated from the
latter region. However, we consider this to be a different
region, because the highest LOD scores at 1q31 were
identified with a recessive model of inheritance, whereas
linkage to 1q25 was obtained with a dominant model.
In the present study, we found linkage to 1q32.3 with
only one marker (D1S425). The highest LOD score was
obtained for all families analyzed jointly ( , un-Zp 1.86
der the dominant model). Although its contribution was
from both family groups, the European families also gave
a relatively high LOD score in a recessive model (Zp
). This could suggest the presence of genetic heter-1.76
ogeneity for this locus. D1S425 is located 7 cM telomeric
from D1S229, which was the first marker used when
linkage was found in the 1q41 region by the University
of California–Los Angeles (UCLA) study (Tsao et al.
1997). The UCLA group also found association with a
microsatellite located in the PARP gene (MIM 173870)
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(Tsao et al. 1999). Despite several studies (Gaffney et al.
1998, 2000; Moser et al. 1998, 1999; Graham et al.
2001) that also show linkage to 1q41, our own unpub-
lished results (as well as those of Delrieu et al. [1999]
and Criswell et al. [2000]) could not detect association
by using the PARP gene microsatellite (data not shown).
That several independent studies fail to replicate the as-
sociation between PARP and SLE, together with the link-
age data from the present study and most other studies,
indicates that PARP is not a major contributor to this
locus.
Our findings at the 1q43 region support earlier find-
ings, mainly in Mexican families, made in the USC study
( [ ]) (Shai et al. 1999). It is dif-NPLp 3.33 Zp 2.41
ficult to interpret the findings from the fine mapping in
the MN study (Gaffney et al. 2000; Graham et al. 2001).
This group found linkage at D1S235 (Z p 1.92), a
marker that is located ∼13 cM centromeric from our
finding but only 7 cM from the locus, at 1q42, that had
been found in African American families in the OK study
(Moser et al. 1998; Gray-McGuire et al. 2000). Clearly,
thorough fine mapping is required within 1q41-43 to
determine the status of this interval.
In summary, we have studied a new set of families from
defined populations, and we have confirmed regions that
were previously identified for SLE, on chromosome 1.
We have also shown that the 1q31 region is a major
SLE-susceptibility locus that may contain a major gene
of importance for the development of this complex dis-
ease in general populations.
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